Profile data is unavailable for this security.
About the company
Recce Pharmaceuticals Ltd is an Australia-based company. The Company is engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the processes utilized by bacteria and viruses to overcome resistance.
- Revenue in AUD (TTM)7.70m
- Net income in AUD-21.43m
- Incorporated2007
- Employees--
- LocationRecce Pharmaceuticals LtdLevel 23180 George St, Salesforce TowerSYDNEY 2000AustraliaAUS
- Phone+61 29000-1907
- Fax+61 28075-4584
- Websitehttps://www.recce.com.au/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitura Health Ltd | 124.04m | 3.28m | 36.45m | 119.00 | 10.19 | 0.7556 | 6.87 | 0.2939 | 0.0054 | 0.0054 | 0.2034 | 0.0728 | 1.69 | 16.43 | 10.46 | -- | 4.11 | 12.75 | 5.72 | 17.62 | 27.21 | 30.97 | 2.43 | 6.06 | 1.05 | 9.50 | 0.2009 | -- | 0.1341 | 298.23 | -5.35 | -- | 129.38 | -- |
| Little Green Pharma Ltd | 38.49m | 5.86m | 36.68m | -- | 6.20 | 0.4264 | 3.78 | 0.9528 | 0.0194 | 0.0194 | 0.1268 | 0.2814 | 0.4262 | 0.8199 | 14.01 | -- | 6.48 | -- | 7.09 | -- | 67.46 | -- | 15.21 | -- | 0.8728 | -4.71 | 0.0541 | -- | 43.67 | -- | 140.77 | -- | -- | -- |
| Inoviq Ltd | 959.32k | -6.93m | 46.46m | 85.00 | -- | 2.20 | -- | 48.43 | -0.0623 | -0.0623 | 0.0086 | 0.1497 | 0.0478 | 3.73 | 0.6725 | -- | -34.52 | -43.01 | -37.36 | -45.87 | 87.45 | 89.08 | -722.62 | -1,543.44 | 5.72 | -- | 0.022 | -- | 21.17 | 57.69 | -5.77 | -- | -- | -- |
| Medical Developments International Ltd | 39.06m | 94.00k | 51.26m | 68.00 | 541.67 | 0.9302 | 15.55 | 1.31 | 0.0008 | 0.0008 | 0.3469 | 0.4891 | 0.6221 | 1.06 | 5.31 | -- | 0.1497 | -16.68 | 0.1738 | -18.92 | 75.35 | 72.70 | 0.2407 | -47.08 | 3.33 | -- | 0.0349 | -- | 17.82 | 11.30 | 100.23 | -24.33 | -34.91 | -- |
| Neurizon Therapeutics Ltd | 1.88m | -16.59m | 64.04m | 52.00 | -- | 16.51 | -- | 34.03 | -0.0334 | -0.0334 | 0.0038 | 0.0056 | 0.2431 | -- | 203.57 | -- | -214.34 | -65.69 | -254.22 | -74.86 | -- | -- | -881.68 | -368.00 | -- | -- | 0.00 | -- | -- | -- | -86.45 | -- | -44.79 | -- |
| Radiopharm Theranostics Ltd | 3.63m | -38.34m | 77.97m | 14.00 | -- | 1.16 | -- | 21.46 | -0.0179 | -0.0179 | 0.0017 | 0.0189 | 0.0458 | -- | 0.6382 | 259,530.70 | -48.38 | -- | -59.58 | -- | 1.08 | -- | -1,055.27 | -- | -- | -7.52 | 0.00 | -- | 1,114.26 | -- | 20.04 | -- | -- | -- |
| Biome Australia Ltd | 18.49m | 214.66k | 91.27m | 30.00 | 440.86 | 19.35 | 199.88 | 4.94 | 0.0009 | 0.0009 | 0.0833 | 0.0212 | 1.83 | 2.39 | 5.14 | -- | 2.12 | -43.09 | 5.42 | -74.65 | 61.27 | 60.84 | 1.16 | -31.29 | 1.02 | 1.80 | 0.3966 | -- | 41.43 | 80.32 | 112.85 | -- | 2.18 | -- |
| Vita Life Sciences Ltd | 85.60m | 9.31m | 142.01m | 124.00 | 15.71 | 2.76 | 29.33 | 1.66 | 0.1655 | 0.1655 | 1.52 | 0.9427 | 1.20 | 2.30 | 6.65 | -- | 13.05 | 15.71 | 17.96 | 22.24 | 60.34 | 59.82 | 10.87 | 12.15 | 2.21 | -- | 0.0409 | 47.99 | 8.28 | 13.37 | -3.26 | 22.87 | 29.67 | 21.67 |
| Recce Pharmaceuticals Ltd | 7.70m | -21.43m | 170.62m | -- | -- | -- | -- | 22.14 | -0.0899 | -0.0899 | 0.0325 | -0.0106 | 0.8203 | -- | 25.91 | -- | -228.15 | -150.15 | -- | -318.01 | -- | -- | -278.12 | -340.57 | -- | -17.98 | 1.49 | -- | 47.14 | 46.35 | -21.33 | -- | 34.71 | -- |
| Starpharma Holdings Ltd | 5.85m | -9.99m | 205.76m | 50.00 | -- | 10.79 | -- | 35.17 | -0.024 | -0.024 | 0.014 | 0.0454 | 0.188 | 0.5663 | 0.9444 | -- | -32.10 | -26.74 | -39.68 | -32.74 | 79.08 | 75.64 | -170.77 | -259.38 | 3.95 | -- | 0.1122 | -- | -40.04 | -2.25 | -22.35 | -- | -19.60 | -- |
| Mayne Pharma Group Ltd | 413.01m | -90.07m | 212.86m | 450.00 | -- | 0.5749 | -- | 0.5154 | -1.14 | -1.19 | 5.22 | 4.56 | 0.3828 | 2.57 | 2.42 | 917,797.80 | -8.35 | -15.32 | -11.61 | -20.87 | 61.06 | 53.04 | -21.81 | -64.51 | 1.16 | -- | 0.1003 | -- | 4.44 | -2.04 | 46.58 | -- | -9.26 | -- |
| Botanix Pharmaceuticals Ltd | 5.76m | -86.40m | 221.64m | 1.00 | -- | 2.71 | -- | 38.50 | -0.0466 | -0.0466 | 0.0031 | 0.0415 | 0.0477 | 0.2477 | 3.48 | -- | -71.53 | -50.27 | -81.16 | -56.02 | 36.99 | -- | -1,500.65 | -1,888.17 | 2.87 | -- | 0.2226 | -- | 856.64 | 102.14 | -522.91 | -- | 63.43 | -- |
Data as of Feb 16 2026. Currency figures normalised to Recce Pharmaceuticals Ltd's reporting currency: Australian Dollar AUD
11.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 15.99m | 5.53% |
| Macquarie Bank Ltd. (Private Banking)as of 17 Apr 2025 | 11.57m | 4.00% |
| FIL Pensions Managementas of 30 Jun 2025 | 5.31m | 1.84% |
| Pictet Asset Management SAas of 30 Jun 2025 | 43.45k | 0.02% |
| Pictet Asset Management (Singapore) Pte Ltd.as of 30 Jun 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2025 - 10 Feb 2026Source: FactSet Research Systems Inc.
